Extended Data Fig. 3: Event-free survival and overall survival of OpACIN-neo. | Nature Medicine

Extended Data Fig. 3: Event-free survival and overall survival of OpACIN-neo.

From: Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Extended Data Fig. 3

a, EFS for the total population of the OpACIN-neo study. A Kaplan-Meier curve for EFS of all patients (n = 86) was generated. The corresponding 95% CI is displayed and was computed using log transformation. b, EFS of the OpACIN-neo study by treatment arm including all patients from arm A (blue, n = 30), arm B (orange, n = 30) and arm C (purple, n = 26). P values were calculated using the log-rank test (two-sided). c, OS for the total population of the OpACIN-neo study. A Kaplan-Meier curve for OS of all patients (n = 86) was generated. d, OS of the OpACIN-neo study by treatment arm including all patients from arm A (blue, n = 30), arm B (orange, n = 30) and arm C (purple, n = 26). a-b, The asterisk denotes the patient who died due to irAEs.

Back to article page